Form 4: Aligos Therapeutics CEO Acquires Stock Options
SEC Form 4 Filing
Lawrence Blatt, CEO of Aligos Therapeutics, acquired stock options for 33,920 shares of common stock on September 4, 2024, according to a Form 4 filing.
Summary
- Lawrence Blatt, the CEO of Aligos Therapeutics, Inc. (ALGS), acquired stock options on September 4, 2024.
- The options grant him the right to buy 33,920 shares of Aligos Therapeutics common stock at an exercise price of $11.74 per share.
- The options vest in equal monthly installments over four years, starting from September 4, 2024, and will be fully vested on the fourth anniversary, contingent upon continued service.
- Following the transaction, Blatt directly owns 33,920 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment. The document simply reports a standard stock option grant to the CEO. It doesn't contain overtly positive or negative information.
Positives
- The acquisition of stock options by the CEO could be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedule implies a four-year commitment from the CEO.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- The vesting schedule of 4 years is typical for such grants.
- Comparing the size of the grant to similar companies like Gilead, Vertex, or Amgen would require analyzing their executive compensation packages.
Stakeholder Impact
- The stock option grant aligns the CEO's interests with those of shareholders, potentially incentivizing him to increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 09/04/2024 | Date of earliest transaction (acquisition of stock options) and Vesting Commencement Date. |
| 09/04/2034 | Expiration date of the stock options. |
| 09/06/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.